Update information
July 2016: This guidance was re‑issued after a change to the commercial arrangements in July 2016. It was verified that this change did not impact cost effectiveness. Recommendation 1.1 and section 2.3 were updated.
Minor changes since publication
January 2014: Implementation section was updated to clarify that abiraterone is recommended as an option for treating castration‑resistant metastatic prostate cancer previously treated with a docetaxel‑containing regimen.
ISBN: 978‑1‑4731‑2003‑7